These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39000029)

  • 1. The Therapeutic Role of NPS-1034 in Pancreatic Ductal Adenocarcinoma as Monotherapy and in Combination with Chemotherapy.
    Luan YZ; Wang CC; Yu CY; Chang YC; Sung WW; Tsai MC
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
    Zhi X; Chen W; Xue F; Liang C; Chen BW; Zhou Y; Wen L; Hu L; Shen J; Bai X; Liang T
    Oncotarget; 2015 Sep; 6(28):26230-41. PubMed ID: 26213847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
    Alhothali M; Mathew M; Iyer G; Lawrence HR; Yang S; Chellappan S; Padmanabhan J
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
    Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
    Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic effects of Argyrin F in pancreatic adenocarcinoma.
    Chen X; Bui KC; Barat S; Thi Nguyen ML; Bozko P; Sipos B; Kalesse M; Malek NP; Plentz RR
    Cancer Lett; 2017 Jul; 399():20-28. PubMed ID: 28408354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
    Momeny M; Alishahi Z; Eyvani H; Esmaeili F; Zaghal A; Ghaffari P; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
    Cell Oncol (Dordr); 2020 Feb; 43(1):81-93. PubMed ID: 31512195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.
    Soltek S; Karakhanova S; Golovastova M; D'Haese JG; Serba S; Nachtigall I; Philippov PP; Werner J; Bazhin AV
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1121-8. PubMed ID: 26105003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells.
    Burmi RS; Maginn EN; Gabra H; Stronach EA; Wasan HS
    Cancer Biol Ther; 2019; 20(1):21-30. PubMed ID: 30261145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
    Ludwig KF; Du W; Sorrelle NB; Wnuk-Lipinska K; Topalovski M; Toombs JE; Cruz VH; Yabuuchi S; Rajeshkumar NV; Maitra A; Lorens JB; Brekken RA
    Cancer Res; 2018 Jan; 78(1):246-255. PubMed ID: 29180468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circular RNA circBFAR promotes the progression of pancreatic ductal adenocarcinoma via the miR-34b-5p/MET/Akt axis.
    Guo X; Zhou Q; Su D; Luo Y; Fu Z; Huang L; Li Z; Jiang D; Kong Y; Li Z; Chen R; Chen C
    Mol Cancer; 2020 May; 19(1):83. PubMed ID: 32375768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
    Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
    Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.
    Burbridge MF; Bossard CJ; Saunier C; Fejes I; Bruno A; Léonce S; Ferry G; Da Violante G; Bouzom F; Cattan V; Jacquet-Bescond A; Comoglio PM; Lockhart BP; Boutin JA; Cordi A; Ortuno JC; Pierré A; Hickman JA; Cruzalegui FH; Depil S
    Mol Cancer Ther; 2013 Sep; 12(9):1749-62. PubMed ID: 23804704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.